AMPHETAMINE AND DEXTROAMPHETAMINE SALTS

Amphetamine And Dextroamphetamine Salts Adverse Events Reported to the FDA Over Time

How are Amphetamine And Dextroamphetamine Salts adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Amphetamine And Dextroamphetamine Salts, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Amphetamine And Dextroamphetamine Salts is flagged as the suspect drug causing the adverse event.

Most Common Amphetamine And Dextroamphetamine Salts Adverse Events Reported to the FDA

What are the most common Amphetamine And Dextroamphetamine Salts adverse events reported to the FDA?

Drug Ineffective	41 (4.75%)
Product Substitution Issue	30 (3.47%)
Completed Suicide	26 (3.01%)
Feeling Abnormal	21 (2.43%)
Asthenia	19 (2.2%)
Fatigue	16 (1.85%)
Anxiety	14 (1.62%)
Headache	14 (1.62%)
Death	12 (1.39%)
Disturbance In Attention	12 (1.39%)
Agitation	11 (1.27%)
	Show More
Fall	11 (1.27%)
Nausea	11 (1.27%)
Pneumonia	11 (1.27%)
Blood Pressure Decreased	10 (1.16%)
Cachexia	10 (1.16%)
Cardiac Arrest	10 (1.16%)
Malaise	10 (1.16%)
Multiple Sclerosis	10 (1.16%)
Suicidal Ideation	10 (1.16%)
Drug Interaction	9 (1.04%)
Insomnia	9 (1.04%)
Depression	8 (.93%)
Dizziness	8 (.93%)
Dyspnoea	8 (.93%)
Hyperhidrosis	8 (.93%)
Irritability	8 (.93%)
Palpitations	8 (.93%)
Poisoning	8 (.93%)
Respiratory Arrest	8 (.93%)
Abnormal Behaviour	7 (.81%)
Activities Of Daily Living Impaired	7 (.81%)
Chest Pain	7 (.81%)
Crying	7 (.81%)
Mood Swings	7 (.81%)
Product Quality Issue	7 (.81%)
Tremor	7 (.81%)
Confusional State	6 (.69%)
Drug Effect Decreased	6 (.69%)
Heart Rate Increased	6 (.69%)
Loss Of Consciousness	6 (.69%)
Anger	5 (.58%)
Blood Pressure Increased	5 (.58%)
Hepatitis C	5 (.58%)
Memory Impairment	5 (.58%)
Overdose	5 (.58%)
Paraesthesia	5 (.58%)
Tension	5 (.58%)
Abdominal Pain Upper	4 (.46%)
Aggression	4 (.46%)
Cardio-respiratory Arrest	4 (.46%)
Condition Aggravated	4 (.46%)
Diarrhoea	4 (.46%)
Drug Abuse	4 (.46%)
Dry Mouth	4 (.46%)
Hypoaesthesia	4 (.46%)
Intentional Drug Misuse	4 (.46%)
Lower Limb Fracture	4 (.46%)
Nervous System Disorder	4 (.46%)
No Therapeutic Response	4 (.46%)
Pain	4 (.46%)
Somnolence	4 (.46%)
Visual Impairment	4 (.46%)
Withdrawal Syndrome	4 (.46%)
Blindness	3 (.35%)
Chest Discomfort	3 (.35%)
Depressed Mood	3 (.35%)
Drug Toxicity	3 (.35%)
Impaired Work Ability	3 (.35%)
Medication Error	3 (.35%)
Mental Impairment	3 (.35%)
Multiple Drug Overdose	3 (.35%)
Myocardial Infarction	3 (.35%)
Psychiatric Symptom	3 (.35%)
Psychotic Disorder	3 (.35%)
Pulmonary Oedema	3 (.35%)
Rash	3 (.35%)
Restlessness	3 (.35%)
Road Traffic Accident	3 (.35%)
Sedation	3 (.35%)
Serotonin Syndrome	3 (.35%)
Speech Disorder	3 (.35%)
Tachycardia	3 (.35%)
Abdominal Pain	2 (.23%)
Abscess Intestinal	2 (.23%)
Adrenocortical Insufficiency Acute	2 (.23%)
Adverse Event	2 (.23%)
Amphetamines Positive	2 (.23%)
Attention Deficit/hyperactivity Dis...	2 (.23%)
Bipolar Disorder	2 (.23%)
Blood Count Abnormal	2 (.23%)
Cardiac Failure Congestive	2 (.23%)
Catatonia	2 (.23%)
Convulsion	2 (.23%)
Cough	2 (.23%)
Decreased Appetite	2 (.23%)
Drug Detoxification	2 (.23%)
Drug Effect Increased	2 (.23%)
Dysarthria	2 (.23%)
Dyspepsia	2 (.23%)
Eating Disorder	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Amphetamine And Dextroamphetamine Salts, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Amphetamine And Dextroamphetamine Salts is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Amphetamine And Dextroamphetamine Salts

What are the most common Amphetamine And Dextroamphetamine Salts adverse events reported to the FDA?

Therapeutic And Nontherapeutic Effe...	70 (8.1%)
Neurological	50 (5.79%)
Product Quality Issues	42 (4.86%)
Anxiety Disorders	37 (4.28%)
Suicidal And Self-injurious Behavio...	37 (4.28%)
Cardiac And Vascular Investigations	28 (3.24%)
Respiratory	24 (2.78%)
Gastrointestinal Signs	22 (2.55%)
Mental Impairment	22 (2.55%)
Medication Errors	21 (2.43%)
Cardiac Arrhythmias	20 (2.31%)
	Show More
Mood Disorders	19 (2.2%)
Injuries	17 (1.97%)
Headaches	16 (1.85%)
Chemical Injury And Poisoning	14 (1.62%)
Psychiatric	14 (1.62%)
Depressed Mood Disorders	13 (1.5%)
Infections - Pathogen Unspecified	13 (1.5%)
Lifestyle Issues	13 (1.5%)
Appetite And General Nutritional	12 (1.39%)
Fatal Outcomes	12 (1.39%)
Skin Appendage Conditions	12 (1.39%)
Demyelinating	11 (1.27%)
Disturbances In Thinking	11 (1.27%)
Sleep Disorders	11 (1.27%)
Psychiatric And Behavioural Symptom...	10 (1.16%)
Cardiac Disorder Signs	9 (1.04%)
Movement Disorders	9 (1.04%)
Personality Disorders	9 (1.04%)
Vision	9 (1.04%)
Bone And Joint Injuries	8 (.93%)
Epidermal And Dermal Conditions	8 (.93%)
Deliria	7 (.81%)
Changes In Physical Activity	6 (.69%)
Schizophrenia And Other Psychotic	6 (.69%)
Viral Infectious	6 (.69%)
Coronary Artery	5 (.58%)
Allergic Conditions	4 (.46%)
Gastrointestinal Motility And Defec...	4 (.46%)
Manic And Bipolar Mood Disorders	4 (.46%)
Muscle	4 (.46%)
Salivary Gland Conditions	4 (.46%)
Toxicology And Therapeutic Drug Mon...	4 (.46%)
Body Temperature Conditions	3 (.35%)
Cognitive And Attention Disorders	3 (.35%)
Communication Disorders	3 (.35%)
Electrolyte And Fluid Balance Condi...	3 (.35%)
Impulse Control	3 (.35%)
Lower Respiratory Tract Disorders	3 (.35%)
Neuromuscular	3 (.35%)
Ocular Neuromuscular	3 (.35%)
Therapeutic Procedures And Supporti...	3 (.35%)
Adrenal Gland	2 (.23%)
Angiedema And Urticaria	2 (.23%)
Central Nervous System Vascular	2 (.23%)
Decreased And Nonspecific Blood Pre...	2 (.23%)
Eating Disorders	2 (.23%)
Economic And Housing Issues	2 (.23%)
Embolism And Thrombosis	2 (.23%)
Eye	2 (.23%)
Heart Failures	2 (.23%)
Hematology Investigations	2 (.23%)
Inner Ear And Viiith Cranial Nerve	2 (.23%)
Metabolic, Nutritional And Blood Ga...	2 (.23%)
Musculoskeletal And Connective Tiss...	2 (.23%)
Nephropathies	2 (.23%)
Physical Examination Topics	2 (.23%)
Reproductive Tract	2 (.23%)
Seizures	2 (.23%)
Upper Respiratory Tract Disorders	2 (.23%)
Arteriosclerosis, Stenosis, Vascula...	1 (.12%)
Bronchial Disorders	1 (.12%)
Coagulopathies And Bleeding Diathes...	1 (.12%)
Endocrine Gland Therapeutic Procedu...	1 (.12%)
Endocrine Investigations	1 (.12%)
Family Issues	1 (.12%)
Hearing	1 (.12%)
Hematological And Lymphoid Tissue T...	1 (.12%)
Hepatobiliary	1 (.12%)
Joint	1 (.12%)
Legal Issues	1 (.12%)
Musculoskeletal And Connective Tiss...	1 (.12%)
Oral Soft Tissue Conditions	1 (.12%)
Pericardial	1 (.12%)
Renal Disorders	1 (.12%)
Sleep Disturbances	1 (.12%)
Somatoform And Factitious	1 (.12%)
Thoracic Disorders	1 (.12%)
Thyroid Gland	1 (.12%)
Tongue Conditions	1 (.12%)
Vascular Hypertensive	1 (.12%)
Water, Electrolyte And Mineral	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Amphetamine And Dextroamphetamine Salts, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Amphetamine And Dextroamphetamine Salts is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.